--- title: "iX Biopharma Ltd. (42C.SG)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/42C.SG.md" symbol: "42C.SG" name: "iX Biopharma Ltd." industry: "Pharmaceuticals" datetime: "2026-05-20T18:19:18.710Z" locales: - [en](https://longbridge.com/en/quote/42C.SG.md) - [zh-CN](https://longbridge.com/zh-CN/quote/42C.SG.md) - [zh-HK](https://longbridge.com/zh-HK/quote/42C.SG.md) --- # iX Biopharma Ltd. (42C.SG) ## Company Overview iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, and insomnia. The company is also developing Wafermine, a racemic ketamine sublingual wafer, which has completed phase-2 clinical trial for the treatment of complex regional pain syndrome, as well as psychiatric conditions, including depression; iXB 401, a sublingual semaglutide wafer that is in pre-clinical development for the treatment of Type 2 Diabetes and Obesity; SL-NAD+, a sublingual NAD+ wafer to increase the body’s NAD+ levels, energy levels, and alertness; iXB 120 that has completed Phase I clinical trial for acute agitation; IXB-214, which has completed Phase I clinical trial for complex regional pain syndrome; and IXB-314 that has completed Phase I clinical trial for treatment resistant depression. | Item | Detail | |------|--------| | Industry | Pharmaceuticals | | Exchange | SG Market | | Website | [www.ixbiopharma.com](https://www.ixbiopharma.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: C > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-20T04:30:13.000Z **Overall: C (0.56)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 4 / 6 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: C #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -5.18% | | | Net Profit YoY | 52.96% | | | P/B Ratio | 21.94 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 374169471.18 | | | Revenue | 7022630.84 | | #### Multi Score Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -53.78% | E | | Profit Margin | -66.70% | E | | Gross Margin | 38.14% | B | | Revenue YoY | -5.18% | D | | Net Profit YoY | 52.96% | B | | Total Assets YoY | 142.48% | A | | Net Assets YoY | 4557.81% | A | | Cash Flow Margin | 122.57% | B | | OCF YoY | -5.18% | D | | Turnover | 0.36 | C | | Gearing Ratio | 37.86% | B | ```chart-data:radar { "title": "Longbridge Financial Score - iX Biopharma Ltd.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-5.18%", "rating": "" }, { "name": "Net Profit YoY", "value": "52.96%", "rating": "" }, { "name": "P/B Ratio", "value": "21.94", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "374169471.18", "rating": "" }, { "name": "Revenue", "value": "7022630.84", "rating": "" } ] }, { "name": "Multi Score", "grade": "C", "indicators": [ { "name": "ROE", "value": "-53.78%", "rating": "E" }, { "name": "Profit Margin", "value": "-66.70%", "rating": "E" }, { "name": "Gross Margin", "value": "38.14%", "rating": "B" }, { "name": "Revenue YoY", "value": "-5.18%", "rating": "D" }, { "name": "Net Profit YoY", "value": "52.96%", "rating": "B" }, { "name": "Total Assets YoY", "value": "142.48%", "rating": "A" }, { "name": "Net Assets YoY", "value": "4557.81%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "122.57%", "rating": "B" }, { "name": "OCF YoY", "value": "-5.18%", "rating": "D" }, { "name": "Turnover", "value": "0.36", "rating": "C" }, { "name": "Gearing Ratio", "value": "37.86%", "rating": "B" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -77.63 | 6/6 | - | - | - | | PB | 21.32 | 6/6 | 309.26 | 51.49 | 4.80 | | PS (TTM) | 51.78 | 6/6 | 28.30 | 14.42 | 2.29 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | CMS (8A8.SG) | B | C | C | A | C | B | | 02 | Haw Par (H02.SG) | B | D | E | A | D | C | | 03 | TJ DaRenTang USD (T14.SG) | A | D | C | B | D | C | | 04 | IX Biopharma (42C.SG) | D | C | C | B | C | C | | 05 | Hyphens Pharma (1J5.SG) | B | D | A | C | C | C | ## Institutional View ### Analyst Rating Distribution > As of 2022-10-01T16:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 0.34 | | Highest Target | undefined | | Lowest Target | undefined | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/42C.SG/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/42C.SG/norm.md) - [Related News](https://longbridge.com/en/quote/42C.SG/news.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**